Publicacions (22) Publicacions de BEATRIZ SOLDEVILLA NAVARRO

2024

  1. Metabolomic profile of neuroendocrine tumors identifies methionine, porphyrin, and tryptophan metabolisms as key dysregulated pathways associated with patient survival

    European Journal of Endocrinology, Vol. 190, Núm. 1, pp. 62-74

  2. Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913)

    Nature Communications, Vol. 15, Núm. 1

2023

  1. Advances in the Treatment of Gastroenteropancreatic Neuroendocrine Carcinomas: Are we Moving Forward?

    Endocrine reviews, Vol. 44, Núm. 4, pp. 724-736

  2. MicroRNA signature and integrative omics analyses define prognostic clusters and key pathways driving prognosis in patients with neuroendocrine neoplasms

    Molecular Oncology, Vol. 17, Núm. 4, pp. 582-597

2021

  1. Comprehensive plasma metabolomic profile of patients with advanced neuroendocrine tumors (Nets). diagnostic and biological relevance

    Cancers, Vol. 13, Núm. 11

2020

  1. Oxidized lipids in the metabolic profiling of neuroendocrine tumors – Analytical challenges and biological implications

    Journal of Chromatography A, Vol. 1625

2019

  1. The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic implications

    European Journal of Cancer, Vol. 123, pp. 118-129

2017

  1. Overexpression of the atpase inhibitory factor 1 favors a non-metastatic phenotype in breast cancer

    Frontiers in Oncology, Vol. 7, Núm. APR

  2. Plasma metabolome and skin proteins in Charcot-Marie-Tooth 1A patients

    PLoS ONE, Vol. 12, Núm. 6

  3. Prognostic relevance of Src activation in stage II-III colon cancer

    Human Pathology, Vol. 67, pp. 119-125

2015

  1. Exosomes enriched in stemness/metastatic-related mRNAS promote oncogenic potential in breast cancer

    Oncotarget, Vol. 6, Núm. 38, pp. 40575-40587

  2. PKA Phosphorylates the ATPase Inhibitory Factor 1 and Inactivates Its Capacity to Bind and Inhibit the Mitochondrial H+-ATP Synthase

    Cell Reports, Vol. 12, Núm. 12, pp. 2143-2155

  3. β-Cryptoxanthin synergistically enhances the antitumoral activity of oxaliplatin through ΔNP73 negative regulation in colon cancer

    Clinical Cancer Research, Vol. 21, Núm. 19, pp. 4398-4409

2014

  1. Tumor-derived exosomes are enriched in ΔNp73, which promotes oncogenic potential in acceptor cells and correlates with patient survival

    Human Molecular Genetics, Vol. 23, Núm. 2, pp. 467-478

2013

  1. Cancer-associated fibroblast and M2 macrophage markers together predict outcome in colorectal cancer patients

    Cancer Science, Vol. 104, Núm. 4, pp. 437-444

  2. Immune-dependent and independent antitumor activity of GM-CSF aberrantly expressed by mouse and human colorectal tumors

    Cancer Research, Vol. 73, Núm. 1, pp. 395-405

  3. Modulation of DNA-induced damage and repair capacity in humans after dietary intervention with lutein-enriched fermented milk.

    PloS one, Vol. 8, Núm. 9

  4. The TP73 complex network: Ready for clinical translation in cancer?

    Genes Chromosomes and Cancer, Vol. 52, Núm. 11, pp. 989-1006

2012

  1. Aberrant epigenetic regulation of bromodomain Brd4 in human colon cancer

    Journal of Molecular Medicine, Vol. 90, Núm. 5, pp. 587-595

2011

  1. EPAS1 mRNA in plasma from colorectal cancer patients is associated with poor outcome in advanced stages

    Oncology Letters, Vol. 2, Núm. 4, pp. 719-724